TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06572189

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Injection of CD-801, a lipid nanoparticle-encapsulated self-replicating RNA encoding hepatocyte nuclear factor 4α (HNF4α)
Description: Receive administration of 100μg of CD-801 via hepatic arterial injection every 14 ± 3 days (the dosing interval will be adjusted based on the tolerability, safety, and therapeutic effect of the subjects), for one treatment cycle. Treatment will continue until the occurrence of disease progression, death, intolerable toxicity, voluntary withdrawal of informed consent, loss to follow-up, initiation of new antitumor treatment, or termination of the study by the investigator (whichever comes first), and completion of the final follow-up and assessment 14 days after the last administration.
Study: NCT06573489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol
Description: Use fospropofol for general anesthesia maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Use propofol for general anesthesia maintenance
Study: NCT05148494

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet Enema
Description: standard pre-op application, see arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pico-Salax
Description: standard pre-op application, see arm description
Study: NCT05919329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT Scan
Description: Undergo PSMA PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT Scan
Description: Undergo PSMA PET/CT
Study: NCT04551469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music
Description: Music intervention for 30 minutes
Study: NCT05362279

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: One month after the pre-test, the post-test will be administered to the nurses who will be in the control group.~Nurses who will be in the experimental group will be given training after the pre-test. A post-test will be administered one month after the training.
Study: NCT05919329

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET/MRI scan
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSMA PET/MRI scan
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study: NCT06449911

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: 300 lines and 10,200 dots will be performed to each half lower two-thirds of the face and submental area of every participant.
Study: NCT05864339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A designed empathy intervention
Description: Students watch 4 smokers' videos, read the textual materials, fill out the HEMs and discuss a quit counseling plan for an assigned smoker using the 5As counseling skilll.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling tutorial
Description: Students watch 4 smokers' videos, read the textual materials, and discuss a quit counseling plan for an assigned smoker using the 5As counseling skill.
Study: NCT05919329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study: NCT05359003

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week physical activity program
Description: Program aimed to achieve the equivalent of 8,000 steps per day (56,000 weekly steps). Includes weekly meetings with a trained health coach.
Study: NCT04417907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 1 week titration
Description: Healthy adults will take 2mg perampanel PO QD for one week followed 4mg perampanel PO QD for five weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 2 week titration
Description: Healthy adults will take 2mg perampanel PO QD for two weeks followed 4mg perampanel PO QD for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel 4mg
Description: Healthy adults will take 4mg perampanel PO QD for six weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healthy adults will take 2mg placebo PO QD for six weeks
Study: NCT05319314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCC19CART
Description: Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
Study: NCT05810961

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod IV
Description: infusion of efgartigimod

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: infusion of placebo
Study: NCT05777174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102
Description: 130 mg administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30-60 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB-102
Description: 130 mg administered by intravenous injection over 30-60 seconds, followed by a 10 mL normal saline flush administered intravenously over 30-60 seconds.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Description: On treatment day, participants will have the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements will be collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements will continue until the sensor no longer detects MB-102 in the body.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MediBeacon Transdermal Glomerular Filtration Rate Measurement System (TGFR)
Description: On treatment day, participants will have the TGFR reusable sensor with disposable adhesive ring placed on their chest, and the MediBeacon® Transdermal GFR Measurement System will be initiated to collect background fluorescence. When this is completed, participants will then receive a single dose of MB-102. Fluorescent measurements will be collected for 12-24 hours. For those with significant renal compromise, fluorescent measurements will continue until the sensor no longer detects MB-102 in the body.
Study: NCT00879294

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Motion sickness wristband
Description: No drugs are involved.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chewing Gum
Description: Patients will be asked to chew gum for 20 minutes, four times daily.
Study: NCT05211037

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Kidney function assessment
Description: kidney clearance measured by scintigraphy
Study: NCT05507606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: osimertinib 80mg/d
Study: NCT05470140

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: WU-NK-101
Description: WU-NK-101 administered on Day 1, Day 8, and Day 15.
Study: NCT05430308

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chlorhexidine scrub
Description: Surgical site selected for performing the thoracoscopy will be cleaned with 4%w/v chlorhexidine gluconate solution for 3 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-iodine
Description: The surgical site selected for performing the thoracoscopy will be just cleaned with normal saline followed by 10% w/v povidone-iodine solution
Study: NCT05507606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab Biosimilar IBI305
Description: Bevacizumab, 7.5mg/kg d1; was discontinued after 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC5, d1; was stopped after 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed, 500mg/m2, d1;Q3W/cycle; was discontinued after 2 years
Study: NCT05484830

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Individualized HDR-approach
Description: Heparin concentration necessary to achieve target ACT \> 480 sec. calculated based on individual HDR-curve.~If HDR slope ˂80 s/IU/mL (reduced sensitivity to heparin), 1000 IU of AT concentrate (Antitrombin III Baxalta®, Takeda Pharma, Vallensbæk Strand, DK). Whole blood concentration of circulating heparin assessed by heparin assays. Additional heparin given as required. After weaning, protamine necessary to reverse circulating heparin calculated according to heparin-protamine titration measurement. After protamine, heparin reversal evaluated with low-range heparin-protamine titration cartridge and additional protamine given as required.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ACT-approach
Description: Initial Heparin 400 IU/kg (500 IU/kg if treated with heparin prior to surgery). ACT Assessment with Hemochron® Signature Elite (ITC, International Technidyne Corp., Edison, NJ, USA).~Additional heparin until ACT \> 480 sec. If ACT \< 480 sec. after despite repeated heparin supplement with 1000 IU of AT III concentrate. Target ACT \> 480 sec. during normothermic CPB, and target ACT \> 700 seconds during hypothermia After weaning, protamine 10mg/mL (0.7 mg of protamine/ 100 IU total heparin administered). Heparin reversal is evaluated with an activated partial thromboplastin (APTT). If APTT \> 40 seconds, additional protamine (25-50 mg i.v.).
Study: NCT06542497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75% phentolamine ophthalmic solution
Description: Once daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily dosing
Study: NCT06315413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation using xenograft and composite plug
Description: Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with injected flowable composite plug which will then be stabilized using 5.0 polypropylene suture material with a figure of eight suture.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket preservation using xenograft and intentionally exposed d-PTFE
Description: Extraction of hopeless teeth will be followed by grafting the socket with xenograft and coverage with d-PTFE membrane which will the be left exposed intentionally. This will be followed by securing the membrane using 5.0 polypropylene suture material with a figure of eight suture.
Study: NCT04950322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1701、CAPOX
Description: SHR-1701 with CAPOX (CAPOX:Oxaliplatin,Capecitabine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo、CAPOX
Description: Placebo with CAPOX (CAPOX:Oxaliplatin,Capecitabine)
Study: NCT06568211

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Persons living with dementia (PLwD) will view 360-degree videos using a commercially-available Virtual Reality (VR) head mounted display that has built-in speakers. While wearing the VR headset, PLwD-participant will be able to visually explore the virtual environments by turning their head to face different directions. Care partner-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the VR headset through the \&amp;#34;screen mirroring\&amp;#34; function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Persons living with dementia (PLwD) will view 360-degree videos using a commercially-available Virtual Reality (VR) head mounted display that has built-in speakers. While wearing the VR headset, PLwD-participant will be able to visually explore the virtual environments by turning their head to face different directions. Care partner-participants will take part in the VR experience concurrently by viewing a tablet that is connected to the VR headset through the \&amp;#34;screen mirroring\&amp;#34; function.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet-Only
Description: PLwD and care partner will view 360-degree videos together on a commercially-available tablet that has built-in speakers. They will be able to visually explore the virtual environment using the touch screen (dragging the view around with their fingers).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tablet-Only
Description: PLwD and care partner will view 360-degree videos together on a commercially-available tablet that has built-in speakers. They will be able to visually explore the virtual environment using the touch screen (dragging the view around with their fingers).
Study: NCT06562335

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booster
Description: See description of arm. The Booster intervention has evolved from the PROfeel intervention. PROfeel is described in: https://doi.org/10.1186/s13063-022-06620-2
Study: NCT06453005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMART Hall Technique or procedure
Description: The SMART Hall technique, a minimally invasive approach in pediatric dentistry for managing caries in primary teeth, involves gentle cavity preparation using hand instruments and minimal local anesthesia. A glass ionomer cement is used for restoration, followed by crown adaptation and cementation. Postoperative care and follow-up assessments at 3 and 6 months are included.~The Stainless Steel Crown (SSC) technique for restoring extensively decayed primary molars involves tooth preparation, crown selection, adaptation, and cementation. Postoperative care and follow-up assessments at 3 and 6 months are also part of the procedure.
Study: NCT06568354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The yoga program was applied to all patients in this group, accompanied by a physiotherapist. Sessions included selected breathing, warm-up, and relaxation exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor control exercises
Description: Motor control exercises with three different progressive phases were applied to all patients in this group accompanied by a physiotherapist.
Study: NCT04769908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Chemotherapy
Description: Systemic Chemotherapy (Oxaliplatin#5-fluorouracil and leucovorin)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib, 8mg or 12mg, po, QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab, IV, 200mg, q3w
Study: NCT06283004

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Downhill walking training
Description: For 8 weeks, downhill walking training will be done 2 times a week at a slope of -10 degrees.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Level walking training
Description: For 8 weeks, level walking training will be done 2 times a week at a slope of 0 degrees.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uphill walking training
Description: For 8 weeks, uphill walking training will be done 2 times a week at a slope of +10 degrees.
Study: NCT04676386

Intervention type: DIAGNOSTIC_TEST
Intervention: Primary Immune Response (PIR) test by Biodesix, Inc.
Description: Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.

Intervention type: DIAGNOSTIC_TEST
Intervention: Primary Immune Response (PIR) test by Biodesix, Inc.
Description: Blood draw for biomarker assessment will be performed at these time-points: pretreatment, start of 3rd cycle and investigator assessed progression. The biomarker analysis will be performed retrospectively.
Study: NCT04942080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CALR allele burden quantification
Description: * DNA extraction from blood sample for CALR mutation quantification (fragment analysis)~* at diagnosis and follow-up (inclusion period: 3 years)~* max 1 sample/year~* secondary outcome: mutational landscape by Next Generation Sequencing (NGS) analysis at diagnosis
Study: NCT04947059

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride combined with continuous saline irrigation
Description: Immediate single intravesical instillation with gemcitabine combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin Hydrochloride combined with continuous saline irrigation
Description: Immediate single intravesical instillation with epirubicin combined with continuous saline irrigation in bladder cancer patients who are treated with a transurethral resection of the tumor
Study: NCT05885347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 360 videos
Description: Caregivers will receive 2h session of 360 videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in 360 videos instantly after the education and after 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR
Description: Caregivers will receive 2h session of VR about caring and medication errors. Then Caregivers will be recorded performed the task worked inVR instantly after the education and after 6 months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AR
Description: Caregivers will receive 2h session of AR videos about caring and medication errors. Then Caregivers will be recorded performed the task worked in AR videos instantly after the education and after 6 months.
Study: NCT05728918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antrodia cinnamomea mycelia
Description: Antrodia cinnamomea mycelia capsule, two capsules/day (600 mg/day) for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule, two capsules/day (600 mg/day) for 3 months
Study: NCT05174559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PreKUnil® LNAA Medical Food for PKU
Description: PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PreKUnil® LNAA Medical Food for PKU
Description: PreKUnil® LNAA Medical Food for PKU is a commercially available active LNAA treatment product for PKU. PreKUnil® inactive LNAA is a customized placebo for this research.
Study: NCT04778176

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: continuous oral delivery of levodopa/carbidopa
Description: The system consists of a reusable custom dental retainer, its case, and a pre-filled, single-use container which continuously releases levodopa/carbidopa into the back of the mouth.
Study: NCT05885347

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Caregivers will follow the routine and then will be recorded performing their labour as a caregiver after 6 months.
Study: NCT05694156

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music-based cognitive training
Description: 8-week music-based cognitive training
Study: NCT05241626

Intervention type: DIAGNOSTIC_TEST
Intervention: AS-OCT
Description: Optical Coherence Tomography (OCT) creates detailed cross-sectional images of the anterior and posterior segments using low coherence interferometry. OCT is a noninvasive, real-time method for evaluating the tear meniscus, total corneal thickness (CT), and corneal epithelial thickness
Study: NCT05335356

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Stelara
Description: 45 mg , 90 mg at Week 0, 4, 16, 28 and 40; Before dosing at Week 16, patients in the Stelara group were randomly assigned in a 1:1 ratio to receive either Bmab 1200 or Stelara

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bmab1200
Description: 45 mg , 90 mg at Week 0, 4, 16, 28 and 40